TELA Bio, Inc. Announces Changes to Its Board of Directors
June 02, 2021 at 02:05 pm EDT
Share
TELA Bio, Inc. announced that it has appointed John Nosenzo, the Chief Commercial Officer of Bioventus Inc., to its board of directors effective June 2, 2021. Concurrent with the appointment of John Nosenzo, as previously announced, current board member Adele Olivia will be stepping down. Following these changes, TELA Bio's board will be composed of seven directors, six of whom are independent.
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
TELA BIO, INC. 
